Loading…
Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD
Introduction Soluble urokinase-type plasminogen activator receptor (suPAR) is upregulated by inflammation and plays a role in the pathogenesis of atherosclerosis. Chronic obstructive pulmonary disease (COPD) is associated with enhanced systemic inflammation and increased risk for atherosclerosis, ho...
Saved in:
| Published in: | Lung 2019-04, Vol.197 (2), p.189-197 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c610t-64ead6b769a10e06d3e1b1f78b59de70e26c3cd8ce636bf80810c668f3aec8043 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c610t-64ead6b769a10e06d3e1b1f78b59de70e26c3cd8ce636bf80810c668f3aec8043 |
| container_end_page | 197 |
| container_issue | 2 |
| container_start_page | 189 |
| container_title | Lung |
| container_volume | 197 |
| creator | Böcskei, Renáta M. Benczúr, Béla Losonczy, György Illyés, Miklós Cziráki, Attila Müller, Veronika Bohács, Anikó Bikov, András |
| description | Introduction
Soluble urokinase-type plasminogen activator receptor (suPAR) is upregulated by inflammation and plays a role in the pathogenesis of atherosclerosis. Chronic obstructive pulmonary disease (COPD) is associated with enhanced systemic inflammation and increased risk for atherosclerosis, however, studies analysing the circulating suPAR levels in COPD are contradictory. The aim of the study was to investigate plasma suPAR concentrations together with markers of arterial stiffness in COPD.
Materials and Methods
Twenty-four patients with COPD and 18 non-COPD, control subjects participated in the study. Plasma suPAR was measured, together with lung volumes, symptom burden, exacerbation history, markers of arterial stiffness and soluble inflammatory biomarkers, such as endothelin-1, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6).
Results
Plasma suPAR levels were higher in COPD (2.84 ± 0.67 ng/ml vs. 2.41 ± 0.57 ng/ml,
p
= 0.03) and were related to lung function measured with FEV
1
(
r
= − 0.65,
p
|
| doi_str_mv | 10.1007/s00408-019-00211-w |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6486892</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A583840073</galeid><sourcerecordid>A583840073</sourcerecordid><originalsourceid>FETCH-LOGICAL-c610t-64ead6b769a10e06d3e1b1f78b59de70e26c3cd8ce636bf80810c668f3aec8043</originalsourceid><addsrcrecordid>eNp9kl9r2zAUxc3YWNNuX2APwzAYfXF3Zdmy_DII2V8oNKzts5Dl60SdImWS3NBvP2Xp2maEoQcJ6XePro5Olr0hcEYAmg8BoAJeAGkLgJKQYvMsm5CKlgVpanieTYBWpCgTdJQdh3ADQBpG6pfZEQVeAqNsknWXzoydwfzau5_ayoDF1d0a87mRYaWtW6DNpyrqWxmdz3-gwvV2IW2fT31Er6XJL6MeBosh5Nrmcxk12hjyjY7LfHYx__QqezFIE_D1_XySXX_5fDX7VpxffP0-m54XihGIBatQ9qxrWCsJILCeIunI0PCubntsAEumqOq5wtR4N3DgBBRjfKASFYeKnmQfd7rrsVthr1IXXhqx9nol_Z1wUov9E6uXYuFuBas4422ZBE7vBbz7NWKIYqWDQmOkRTcGURLe1Mk3ThL67h_0xo3epudtKdaWnNH2kVpIg0LbwaV71VZUTGtOeZV-kSaqOEAl4zE16SwOOm3v8WcH-DR6XGl1sOD9k4IlShOXIX171M6GfbDcgcq7EDwOD-YRENvIiV3kRIqc-BM5sUlFb5_a_lDyN2MJoDsgpCO7QP_o1X9kfwMjvuBN</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2186928639</pqid></control><display><type>article</type><title>Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD</title><source>Springer Link</source><creator>Böcskei, Renáta M. ; Benczúr, Béla ; Losonczy, György ; Illyés, Miklós ; Cziráki, Attila ; Müller, Veronika ; Bohács, Anikó ; Bikov, András</creator><creatorcontrib>Böcskei, Renáta M. ; Benczúr, Béla ; Losonczy, György ; Illyés, Miklós ; Cziráki, Attila ; Müller, Veronika ; Bohács, Anikó ; Bikov, András</creatorcontrib><description>Introduction
Soluble urokinase-type plasminogen activator receptor (suPAR) is upregulated by inflammation and plays a role in the pathogenesis of atherosclerosis. Chronic obstructive pulmonary disease (COPD) is associated with enhanced systemic inflammation and increased risk for atherosclerosis, however, studies analysing the circulating suPAR levels in COPD are contradictory. The aim of the study was to investigate plasma suPAR concentrations together with markers of arterial stiffness in COPD.
Materials and Methods
Twenty-four patients with COPD and 18 non-COPD, control subjects participated in the study. Plasma suPAR was measured, together with lung volumes, symptom burden, exacerbation history, markers of arterial stiffness and soluble inflammatory biomarkers, such as endothelin-1, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6).
Results
Plasma suPAR levels were higher in COPD (2.84 ± 0.67 ng/ml vs. 2.41 ± 0.57 ng/ml,
p
= 0.03) and were related to lung function measured with FEV
1
(
r
= − 0.65,
p
< 0.01) and symptom burden determined with the modified Medical Research Council questionnaire (
r
= 0.55,
p
< 0.05). Plasma suPAR concentrations correlated with various measures of arterial stiffness in all subjects, but only with ejection duration in COPD (
r
= − 0.44,
p
= 0.03).
Conclusions
Plasma suPAR levels are elevated in COPD and relate to arterial stiffness. Our results suggest that suPAR may be a potential link between COPD and atherosclerosis.</description><identifier>ISSN: 0341-2040</identifier><identifier>EISSN: 1432-1750</identifier><identifier>DOI: 10.1007/s00408-019-00211-w</identifier><identifier>PMID: 30820636</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aged ; Arteriosclerosis ; Atherosclerosis ; Biological markers ; Biomarkers ; Biomarkers - blood ; C-reactive protein ; C-Reactive Protein - analysis ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - diagnosis ; Cardiovascular Diseases - physiopathology ; Case-Control Studies ; Chronic obstructive lung disease ; Chronic obstructive pulmonary disease ; COPD ; Correlation analysis ; Cross-Sectional Studies ; Ejection ; Endothelin 1 ; Endothelin-1 - blood ; Endothelins ; Female ; Forced Expiratory Volume ; Hormone replacement therapy ; Humans ; Inflammation ; Interleukin 6 ; Interleukin-6 - blood ; Interleukins ; Lung - physiopathology ; Lung diseases ; Male ; Medical research ; Medicine ; Medicine & Public Health ; Middle Aged ; Obstructive lung disease ; Pathogenesis ; Patients ; Pneumology/Respiratory System ; Proteins ; Pulmonary Disease, Chronic Obstructive - blood ; Pulmonary Disease, Chronic Obstructive - diagnosis ; Pulmonary Disease, Chronic Obstructive - physiopathology ; Receptors, Urokinase Plasminogen Activator - blood ; Respiratory function ; Severity of Illness Index ; Stiffness ; U-Plasminogen activator ; Up-Regulation ; Urokinase ; Vascular Stiffness ; Vital Capacity</subject><ispartof>Lung, 2019-04, Vol.197 (2), p.189-197</ispartof><rights>The Author(s) 2019</rights><rights>COPYRIGHT 2019 Springer</rights><rights>Lung is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c610t-64ead6b769a10e06d3e1b1f78b59de70e26c3cd8ce636bf80810c668f3aec8043</citedby><cites>FETCH-LOGICAL-c610t-64ead6b769a10e06d3e1b1f78b59de70e26c3cd8ce636bf80810c668f3aec8043</cites><orcidid>0000-0002-8983-740X ; 0000-0001-5461-6730 ; 0000-0002-0211-5237 ; 0000-0002-1398-3187</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30820636$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Böcskei, Renáta M.</creatorcontrib><creatorcontrib>Benczúr, Béla</creatorcontrib><creatorcontrib>Losonczy, György</creatorcontrib><creatorcontrib>Illyés, Miklós</creatorcontrib><creatorcontrib>Cziráki, Attila</creatorcontrib><creatorcontrib>Müller, Veronika</creatorcontrib><creatorcontrib>Bohács, Anikó</creatorcontrib><creatorcontrib>Bikov, András</creatorcontrib><title>Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD</title><title>Lung</title><addtitle>Lung</addtitle><addtitle>Lung</addtitle><description>Introduction
Soluble urokinase-type plasminogen activator receptor (suPAR) is upregulated by inflammation and plays a role in the pathogenesis of atherosclerosis. Chronic obstructive pulmonary disease (COPD) is associated with enhanced systemic inflammation and increased risk for atherosclerosis, however, studies analysing the circulating suPAR levels in COPD are contradictory. The aim of the study was to investigate plasma suPAR concentrations together with markers of arterial stiffness in COPD.
Materials and Methods
Twenty-four patients with COPD and 18 non-COPD, control subjects participated in the study. Plasma suPAR was measured, together with lung volumes, symptom burden, exacerbation history, markers of arterial stiffness and soluble inflammatory biomarkers, such as endothelin-1, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6).
Results
Plasma suPAR levels were higher in COPD (2.84 ± 0.67 ng/ml vs. 2.41 ± 0.57 ng/ml,
p
= 0.03) and were related to lung function measured with FEV
1
(
r
= − 0.65,
p
< 0.01) and symptom burden determined with the modified Medical Research Council questionnaire (
r
= 0.55,
p
< 0.05). Plasma suPAR concentrations correlated with various measures of arterial stiffness in all subjects, but only with ejection duration in COPD (
r
= − 0.44,
p
= 0.03).
Conclusions
Plasma suPAR levels are elevated in COPD and relate to arterial stiffness. Our results suggest that suPAR may be a potential link between COPD and atherosclerosis.</description><subject>Aged</subject><subject>Arteriosclerosis</subject><subject>Atherosclerosis</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>C-reactive protein</subject><subject>C-Reactive Protein - analysis</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - diagnosis</subject><subject>Cardiovascular Diseases - physiopathology</subject><subject>Case-Control Studies</subject><subject>Chronic obstructive lung disease</subject><subject>Chronic obstructive pulmonary disease</subject><subject>COPD</subject><subject>Correlation analysis</subject><subject>Cross-Sectional Studies</subject><subject>Ejection</subject><subject>Endothelin 1</subject><subject>Endothelin-1 - blood</subject><subject>Endothelins</subject><subject>Female</subject><subject>Forced Expiratory Volume</subject><subject>Hormone replacement therapy</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Interleukin 6</subject><subject>Interleukin-6 - blood</subject><subject>Interleukins</subject><subject>Lung - physiopathology</subject><subject>Lung diseases</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Obstructive lung disease</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Pneumology/Respiratory System</subject><subject>Proteins</subject><subject>Pulmonary Disease, Chronic Obstructive - blood</subject><subject>Pulmonary Disease, Chronic Obstructive - diagnosis</subject><subject>Pulmonary Disease, Chronic Obstructive - physiopathology</subject><subject>Receptors, Urokinase Plasminogen Activator - blood</subject><subject>Respiratory function</subject><subject>Severity of Illness Index</subject><subject>Stiffness</subject><subject>U-Plasminogen activator</subject><subject>Up-Regulation</subject><subject>Urokinase</subject><subject>Vascular Stiffness</subject><subject>Vital Capacity</subject><issn>0341-2040</issn><issn>1432-1750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kl9r2zAUxc3YWNNuX2APwzAYfXF3Zdmy_DII2V8oNKzts5Dl60SdImWS3NBvP2Xp2maEoQcJ6XePro5Olr0hcEYAmg8BoAJeAGkLgJKQYvMsm5CKlgVpanieTYBWpCgTdJQdh3ADQBpG6pfZEQVeAqNsknWXzoydwfzau5_ayoDF1d0a87mRYaWtW6DNpyrqWxmdz3-gwvV2IW2fT31Er6XJL6MeBosh5Nrmcxk12hjyjY7LfHYx__QqezFIE_D1_XySXX_5fDX7VpxffP0-m54XihGIBatQ9qxrWCsJILCeIunI0PCubntsAEumqOq5wtR4N3DgBBRjfKASFYeKnmQfd7rrsVthr1IXXhqx9nol_Z1wUov9E6uXYuFuBas4422ZBE7vBbz7NWKIYqWDQmOkRTcGURLe1Mk3ThL67h_0xo3epudtKdaWnNH2kVpIg0LbwaV71VZUTGtOeZV-kSaqOEAl4zE16SwOOm3v8WcH-DR6XGl1sOD9k4IlShOXIX171M6GfbDcgcq7EDwOD-YRENvIiV3kRIqc-BM5sUlFb5_a_lDyN2MJoDsgpCO7QP_o1X9kfwMjvuBN</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Böcskei, Renáta M.</creator><creator>Benczúr, Béla</creator><creator>Losonczy, György</creator><creator>Illyés, Miklós</creator><creator>Cziráki, Attila</creator><creator>Müller, Veronika</creator><creator>Bohács, Anikó</creator><creator>Bikov, András</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8983-740X</orcidid><orcidid>https://orcid.org/0000-0001-5461-6730</orcidid><orcidid>https://orcid.org/0000-0002-0211-5237</orcidid><orcidid>https://orcid.org/0000-0002-1398-3187</orcidid></search><sort><creationdate>20190401</creationdate><title>Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD</title><author>Böcskei, Renáta M. ; Benczúr, Béla ; Losonczy, György ; Illyés, Miklós ; Cziráki, Attila ; Müller, Veronika ; Bohács, Anikó ; Bikov, András</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c610t-64ead6b769a10e06d3e1b1f78b59de70e26c3cd8ce636bf80810c668f3aec8043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Arteriosclerosis</topic><topic>Atherosclerosis</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>C-reactive protein</topic><topic>C-Reactive Protein - analysis</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - diagnosis</topic><topic>Cardiovascular Diseases - physiopathology</topic><topic>Case-Control Studies</topic><topic>Chronic obstructive lung disease</topic><topic>Chronic obstructive pulmonary disease</topic><topic>COPD</topic><topic>Correlation analysis</topic><topic>Cross-Sectional Studies</topic><topic>Ejection</topic><topic>Endothelin 1</topic><topic>Endothelin-1 - blood</topic><topic>Endothelins</topic><topic>Female</topic><topic>Forced Expiratory Volume</topic><topic>Hormone replacement therapy</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Interleukin 6</topic><topic>Interleukin-6 - blood</topic><topic>Interleukins</topic><topic>Lung - physiopathology</topic><topic>Lung diseases</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Obstructive lung disease</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Pneumology/Respiratory System</topic><topic>Proteins</topic><topic>Pulmonary Disease, Chronic Obstructive - blood</topic><topic>Pulmonary Disease, Chronic Obstructive - diagnosis</topic><topic>Pulmonary Disease, Chronic Obstructive - physiopathology</topic><topic>Receptors, Urokinase Plasminogen Activator - blood</topic><topic>Respiratory function</topic><topic>Severity of Illness Index</topic><topic>Stiffness</topic><topic>U-Plasminogen activator</topic><topic>Up-Regulation</topic><topic>Urokinase</topic><topic>Vascular Stiffness</topic><topic>Vital Capacity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Böcskei, Renáta M.</creatorcontrib><creatorcontrib>Benczúr, Béla</creatorcontrib><creatorcontrib>Losonczy, György</creatorcontrib><creatorcontrib>Illyés, Miklós</creatorcontrib><creatorcontrib>Cziráki, Attila</creatorcontrib><creatorcontrib>Müller, Veronika</creatorcontrib><creatorcontrib>Bohács, Anikó</creatorcontrib><creatorcontrib>Bikov, András</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Lung</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Böcskei, Renáta M.</au><au>Benczúr, Béla</au><au>Losonczy, György</au><au>Illyés, Miklós</au><au>Cziráki, Attila</au><au>Müller, Veronika</au><au>Bohács, Anikó</au><au>Bikov, András</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD</atitle><jtitle>Lung</jtitle><stitle>Lung</stitle><addtitle>Lung</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>197</volume><issue>2</issue><spage>189</spage><epage>197</epage><pages>189-197</pages><issn>0341-2040</issn><eissn>1432-1750</eissn><abstract>Introduction
Soluble urokinase-type plasminogen activator receptor (suPAR) is upregulated by inflammation and plays a role in the pathogenesis of atherosclerosis. Chronic obstructive pulmonary disease (COPD) is associated with enhanced systemic inflammation and increased risk for atherosclerosis, however, studies analysing the circulating suPAR levels in COPD are contradictory. The aim of the study was to investigate plasma suPAR concentrations together with markers of arterial stiffness in COPD.
Materials and Methods
Twenty-four patients with COPD and 18 non-COPD, control subjects participated in the study. Plasma suPAR was measured, together with lung volumes, symptom burden, exacerbation history, markers of arterial stiffness and soluble inflammatory biomarkers, such as endothelin-1, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6).
Results
Plasma suPAR levels were higher in COPD (2.84 ± 0.67 ng/ml vs. 2.41 ± 0.57 ng/ml,
p
= 0.03) and were related to lung function measured with FEV
1
(
r
= − 0.65,
p
< 0.01) and symptom burden determined with the modified Medical Research Council questionnaire (
r
= 0.55,
p
< 0.05). Plasma suPAR concentrations correlated with various measures of arterial stiffness in all subjects, but only with ejection duration in COPD (
r
= − 0.44,
p
= 0.03).
Conclusions
Plasma suPAR levels are elevated in COPD and relate to arterial stiffness. Our results suggest that suPAR may be a potential link between COPD and atherosclerosis.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>30820636</pmid><doi>10.1007/s00408-019-00211-w</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8983-740X</orcidid><orcidid>https://orcid.org/0000-0001-5461-6730</orcidid><orcidid>https://orcid.org/0000-0002-0211-5237</orcidid><orcidid>https://orcid.org/0000-0002-1398-3187</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0341-2040 |
| ispartof | Lung, 2019-04, Vol.197 (2), p.189-197 |
| issn | 0341-2040 1432-1750 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6486892 |
| source | Springer Link |
| subjects | Aged Arteriosclerosis Atherosclerosis Biological markers Biomarkers Biomarkers - blood C-reactive protein C-Reactive Protein - analysis Cardiovascular Diseases - blood Cardiovascular Diseases - diagnosis Cardiovascular Diseases - physiopathology Case-Control Studies Chronic obstructive lung disease Chronic obstructive pulmonary disease COPD Correlation analysis Cross-Sectional Studies Ejection Endothelin 1 Endothelin-1 - blood Endothelins Female Forced Expiratory Volume Hormone replacement therapy Humans Inflammation Interleukin 6 Interleukin-6 - blood Interleukins Lung - physiopathology Lung diseases Male Medical research Medicine Medicine & Public Health Middle Aged Obstructive lung disease Pathogenesis Patients Pneumology/Respiratory System Proteins Pulmonary Disease, Chronic Obstructive - blood Pulmonary Disease, Chronic Obstructive - diagnosis Pulmonary Disease, Chronic Obstructive - physiopathology Receptors, Urokinase Plasminogen Activator - blood Respiratory function Severity of Illness Index Stiffness U-Plasminogen activator Up-Regulation Urokinase Vascular Stiffness Vital Capacity |
| title | Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T20%3A10%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Soluble%20Urokinase-Type%20Plasminogen%20Activator%20Receptor%20and%20Arterial%20Stiffness%20in%20Patients%20with%20COPD&rft.jtitle=Lung&rft.au=B%C3%B6cskei,%20Ren%C3%A1ta%20M.&rft.date=2019-04-01&rft.volume=197&rft.issue=2&rft.spage=189&rft.epage=197&rft.pages=189-197&rft.issn=0341-2040&rft.eissn=1432-1750&rft_id=info:doi/10.1007/s00408-019-00211-w&rft_dat=%3Cgale_pubme%3EA583840073%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c610t-64ead6b769a10e06d3e1b1f78b59de70e26c3cd8ce636bf80810c668f3aec8043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2186928639&rft_id=info:pmid/30820636&rft_galeid=A583840073&rfr_iscdi=true |